Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.

Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ

Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.

Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW

A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).

Russo RJ, Silva PD, Teirstein PS, Attubato MJ, Davidson CJ, DeFranco AC, Fitzgerald PJ, Goldberg SL, Hermiller JB, Leon MB, Ling FS, Lucisano JE, Schatz RA, Wong SC, Weissman NJ, Zientek DM, AVID Investigators

Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).

Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA, TRA-PCI Investigators

Percutaneous revascularization is the preferred strategy for patients with significant left main coronary stenosis.

Teirstein PS

A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience.

Dixon SR, Henriques JP, Mauri L, Sjauw K, Civitello A, Kar B, Loyalka P, Resnic FS, Teirstein P, Makkar R, Palacios IF, Collins M, Moses J, Benali K, O'Neill WW

Safety and performance of targeted renal therapy: the Be-RITe! Registry.

Weisz G, Filby SJ, Cohen MG, Allie DE, Weinstock BS, Kyriazis D, Walker CM, Moses JW, Danna P, Fearon WF, Sachdev N, Wiechmann BN, Vora K, Findeiss L, Price MJ, Mehran R, Leon MB, Teirstein PS

Change we can believe in: the hyper-evolution of percutaneous coronary intervention for unprotected left main disease with drug-eluting stents.

Price MJ, Kandzari DE, Teirstein PS

Quality of life with PCI versus medical therapy in stable coronary disease.

Brown RA, Teirstein PS, Kandzari DE